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MBTPS2 mutations cause defective regulated
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osteogenesis imperfecta
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Osteogenesis imperfecta (OI) is a collagen-related bone dysplasia. We identiﬁed an X-linked
recessive form of OI caused by defects in MBTPS2, which encodes site-2 metalloprotease
(S2P). MBTPS2 missense mutations in two independent kindreds with moderate/severe OI
cause substitutions at highly conserved S2P residues. Mutant S2P has normal stability, but
impaired functioning in regulated intramembrane proteolysis (RIP) of OASIS, ATF6 and SREBP
transcription factors, consistent with decreased proband secretion of type I collagen. Further,
hydroxylation of the collagen lysine residue (K87) critical for crosslinking is reduced in
proband bone tissue, consistent with decreased lysyl hydroxylase 1 in proband osteoblasts.
Reduced collagen crosslinks presumptively undermine bone strength. Also, proband
osteoblasts have broadly defective differentiation. These mutations provide evidence that RIP
plays a fundamental role in normal bone development.
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O
steogenesis imperfecta (OI), or ‘brittle bone disease’,
is a well-known heritable skeletal dysplasia. Affected
individuals have low bone mass and increased fracture
susceptibility. OI is genetically heterogeneous. Most cases have
autosomal-dominant mutations in the type I collagen genes,
COL1A1 or COL1A2 (ref. 1). More recently, multiple genes
causing mostly autosomal recessive forms of OI were delineated,
generating a new paradigm for OI as a collagen-related disorder.
The products of these genes (CRTAP, LEPRE1, PPIB,
FKBP10, PLOD2, SERPINH1, BMP1, SERPINF1, IFITM5 and
SPARC) interact with collagen post-translationally for prolyl
3-hydroxylation, folding, processing, ﬁbrillogenesis, cross-linking
and/or mineralization1,2. No cases of X-linked OI have been
reported.
Regulated intramembrane proteolysis (RIP) involves cleavage
of membrane-spanning regulatory proteins by proteases
within the plane of the membrane3. The three intramembrane
cleaving protease (iCLiP) families include serine proteases, site-2
metalloprotease (S2P) and aspartyl proteases. The best-described
RIP-mediated signalling in humans involves sequential cleavage
of diverse substrates by site-1 protease (S1P), a serine protease
encoded by membrane-bound transcription factor peptidase,
site 1 (MBTPS1), and S2P, encoded by membrane-bound
transcription factor peptidase, site 2 (MBTPS2). S1P and S2P
are located in the Golgi membrane. They cleave regulatory
proteins transported from the ER membrane in times of ER stress
or decreased sterol metabolites, releasing mature N-terminal
fragments that shuttle to the nucleus and activate gene
transcription. These substrates include old astrocyte speciﬁcally
induced substance (OASIS)/cAMP responsive element binding
protein 3-like 1 (CREB3L1), a transcription factor expressed
in astrocytes and osteoblasts, activating transcription factor 6
(ATF6), a component of the unfolded protein response pathway
and sterol regulatory element binding protein (SREBP), involved
in cholesterol synthesis4–6. MBTPS2 missense mutations were
previously identiﬁed in the related dermatological conditions
IFAP/BRESHECK (ichthyosis follicularis, atrichia, and
photophobia, OMIM #308205)7,8 and keratosis follicularis
spinulosa decalvans (KFSD, X-linked, OMIM #308800)9.
In this report, we present two independent OI pedigrees with
an X-linked inheritance pattern, and without symptoms of IFAP/
KFSD. Linkage analysis and next-generation sequencing (NGS)
identiﬁed a novel MBTPS2 missense mutation in each pedigree.
The resulting substitutions are in or near the S2P NPDG motif
crucial for metal ion coordination10. Mutant S2P protein is stable
but cleavage or activation of S2P substrates OASIS and ATF6,
respectively, is impaired, consistent with reduced proband
collagen secretion. Osteoblasts with mutant S2P have defective
differentiation, and bone tissue collagen from one proband has
decreased hydroxylation of the critical crosslinking lysine residue.
These X-linked OI-causing mutations extend RIP functioning to
normal bone formation.
Results
Clinical features. Family I. From an extended Thai OI pedigree,
6 of 12 affected males were examined (Fig. 1a,b and
Supplementary Table 1). The proband (P1/I; V7) had prenatal
fractures of ribs and long bones (Fig. 2a). At 2 years, his physical
exam was notable for moderate short stature, blue sclerae, pectus
carinatum and bowing of lower extremity long bones. His L2–L4
bone mineral density z-score¼  4.7 (0.315 g cm 2). Affected
adult males had fractures beginning during gestation, short
stature, white sclerae, variable scoliosis and pectal deformity,
striking tibial anterior angulation and generalized osteopenia
(see Case Reports).
Family II. A non-consanguineous German pedigree has two
affected males, the 26-year-old proband (P1/II) and his
68-year-old maternal uncle (P2/II) (Fig. 2c; Supplementary
Fig. 2a and Supplementary Table 1). As a newborn, the proband
was noted to have bowing of humeri, radii and tibiae, and
fractures of femora, ribs and clavicles, as well as generalized
osteopenia (Fig. 2b and Supplementary Fig. 2b). Both patients
had numerous fractures of upper and lower extremity long bones
during childhood, but fractures declined post puberty. Both have
white sclerae, kyphoscoliosis with anterior vertebral wedging and
short stature, with ﬁnal height of 5–6-year-old males. The uncle
has severe pectus excavatum.
None of the affected individuals had ichthyosis follicularis,
alopecia, photophobia, intellectual disability or seizures.
Mutation identiﬁcation. Sequencing of a set of genes involved
in OI and bone fragility (ALPL, BMP1, COL1A1, COL1A2,
CREB3L1, CRTAP, FKBP10, IFITM5, LEPRE1, LRP5, PLOD2,
PLS3, PPIB, SERPINF1, SERPINH1, SP7, TMEM38B and WNT1)
did not reveal functional changes in the probands of either
pedigree. Each proband had a neutral COL1 single-nucleotide
polymorphism (SNP) that was inherited from his healthy father
(Supplementary Fig. 3). Interestingly, the urinary lysyl
pyridinoline (LP) to hydroxylysyl pyridinoline (HP) ratio, which
has been suggested as a diagnostic marker for OI11, was markedly
elevated in an adult from Family I and two adults from Family II
(0.305–0.450 patients versus controls 0.211±0.008) and in the
index case from Family I (0.319 versus paediatric controls
0.208±0.030) (Supplementary Table 2). The LP/HP ratio was not
elevated in a carrier from each OI Family, or in a case of IFAP.
The elevated LP/HP ratio is similar to ﬁndings in a mouse model
of type IX OI12, although X-OI probands have normal PPIB
sequences.
X-chromosome inactivation studies of ﬁve obligate carriers
from Family I showed a skewed pattern of inactivation
(Supplementary Fig. 4). Linkage analysis of the X-chromosome
in Family I deﬁned a 21.6-Mb critical region on Xp22 from
markers DXS7108 to DXS1067 (LOD score 3.31) (Fig. 1b and
Supplementary Table 3). Comparative genomic hybridization
(CGH) analysis did not reveal imbalances in the critical region,
which was then sequenced by NGS in affected male IV17 and
unaffected male IV10. After excluding known SNPs, and variants
present in the unaffected relative, two candidates remained.
A mutation in MBTPS2 exon 11, c.1376A4G (nucleotide:
NM_015884.3, GRCh38) predicting a p.N459S substitution
(protein: NP_056968.1), was conﬁrmed by Sanger sequencing of
proband DNA (Fig. 2c), segregated with OI in the pedigree
(Fig. 1b) and was absent in 644 X chromosomes of unrelated
Thai controls (181 females, 282 males). A FAM48B1 variant,
c.532G4A (p.V178M), occurred in 4 of 22 alleles from Thai
controls (Supplementary Table 4).
In Family II, SNP-genome-wide linkage analysis supported
X-linked recessive inheritance, despite normal X-inactivation
(0.70) in the mother of P1/II, with a positive LOD score in a
30-Mb region of chromosome X between rs11094708 and
rs5906168 (Supplementary Fig. 1a and Supplementary Table 5).
In view of the modest positive LOD score, the entire X-exome was
sequenced by NGS, resulting in two variants with population
frequencies below 0.5% within the 30-Mb critical region. The ﬁrst
variant, a hemizygous c.1778G4A (p.R593H) missense SNP in
CCDC120, was detected in proband P1/II but not in his affected
uncle (P2/II). The second variant, a hemizygous c.1515G4C
mutation in MBTPS2 (p.L505F; Supplementary Fig. 1b),
co-segregated with the phenotype and was also found in a
heterozygous state in the proband’s mother (Fig. 2d).
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Multiple programs (Polyphen2, SIFT, Provean, Mutation-
Taster) predict both MBTPS2 (S2P) variants p.N459S and
p.L505F as pathogenic since they are likely to interfere with
function (Supplementary Table 6). Residues N459 and L505 are
highly conserved in S2P, as identiﬁed by ClustalX (Fig. 2e), as well
as ClustalW and Boxshade (for p.L505F). Neither of the MBTPS2
mutations, c.1376A4G (p.N459S) and c.1515G4C (p.L505F)
are present in the Leiden Open Variation Database (LOVD),
Exome Aggregation Consortium (ExAC), the Exome Variant
Server (EVS), 1000 Genomes Browser and dbSNP Build 144
variant databases (Supplementary Table 6). N459 is the ﬁrst
residue of the NPDG motif, which is important for metal ion
coordination10.
Effect of MBTPS2 mutations on transcripts and protein.
MBTPS2 transcript levels were not reduced in ﬁbroblasts with OI,
IFAP (p.R429H) or KFSD (p.N508S) mutations, by real-time
RT–PCR (Fig. 3a). In addition, S2P protein displayed normal
stability in these cells on immunoblot (Fig. 3b).
Effect of mutant S2P on RIP functions. We examined the
impact of S2P substitutions on activation of RIP substrates
OASIS, ATF6 and SREBP (Fig. 4a–c). On western blot, mature
intracellular OASIS cleavage fragment (50 kDa, S1P/S2P cleaved)
was decreased, while the 55-kDa cleavage product (S1P cleaved)
was increased, in ﬁbroblasts with each mutation and in S2P
p.L505F osteoblasts, indicating S2P cleavage impairment in
OI probands comparable to IFAP and KFSD cells (Fig. 4a).
Treatment with ALLN (N-acetyl-leucyl-leucyl-norleucinal) to
prevent degradation of OASIS cleavage products increased the
total OASIS detected in all ﬁbroblast and osteoblast cell lines, as
well as the relative proportion of fully cleaved OASIS in normal
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Figure 1 | Extended pedigree of Family I with linkage and segregation analyses. (a) Extended pedigree of Family I. The pedigree contains 12 affected
members (blackened symbols), with seven living and ﬁve deceased (diagonally crossed). Clinical assessments and blood samples were obtained from
18 individuals (short horizontal bars above symbols), including six affected. Dotted circles denote obligate carriers. Arrow indicates Proband P1/I.
(b) Linkage and segregation analysis. Thai pedigree shows linkage of mutation with X chromosome and cosegregation of the mutation with phenotype.
X-chromosomal markers are shown from Xpter to Xcen (full list of markers in Supplementary Table 3). Linked markers in squares are shown in relation to
the members’ status. The MBTPS2 c.1376A4G (p.N459S) mutation segregated with phenotype in all affected members. The mutation introduces a BsgI
cleavage site, resulting in 375 and 305 bp bands. The normal allele generates the undigested 680bp band. Marker ¼ 100 bp marker;  ve, negative control
with no DNA added; an arrowhead indicates the 680bp band. (c) Pedigree of Family IIA. The segregation analysis was done on all family members still alive
at the time of sampling, that is all but individuals I/1, I/2 and II/4. The index patient P1/II and his maternal uncle P2/II show very similar clinical ﬁndings
compatible with the diagnosis osteogenesis imperfecta type III/IV. The mother of P1/II is of normal height, whereas the maternal grandmother is only
155 cm (o3rd centile), but does not show any signs of osteogenesis imperfecta.
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control, IFAP and KFSD ﬁbroblasts and normal control osteo-
blasts, more than in OI cells (Fig. 4a). Treatment with tunicamycin
to induce ER stress had no further effect on OASIS cleavage.
An ATF6 reporter was co-transfected with MBTPS2 expression
constructs containing normal, OI-causing (p.N459S or p.L505F)
or IFAP/BRESHECK (p.R429H)7,8 sequences into CHO-M19
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Figure 2 | Clinical features of probands and mutation identiﬁcation. (a) Left, Proband 1/I had blue sclerae, pectus carinatum and anteriorly bowed legs at
2 years of age. Centre, radiographs showed fractures of ribs, humeri, femora and tibiae on day 1 of life. Right, undertubulation and minimal cortex of lower
long bones at 2 years of age. (b) Left, Proband 1/II at age 20 years presenting with signiﬁcant rhizomelia of upper and lower extremities. Centre,
radiographs at birth showed bowed tibiae and ﬁbulae (left leg shown). Right, radiographs revealed kyphoscoliosis with anterior vertebral wedging, and ﬂat,
biconcave vertebral bodies with signiﬁcant osteoporosis at 13 years of age. (c) MBTPS2 genomic DNA sequence reveals the c.1376A4G mutation
(p.N459S) in proband P1/I and his heterozygous mother, but not in the proband’s father. (d) Sequence of P1/II genomic DNA shows the MBTPS2
c.1515G4C mutation (p.L505F), which also occurs in heterozygous form in his mother, but is not present in the proband’s father. (e) Species comparison of
the S2P amino-acid sequence according to ClustalX. Residues shaded in green denote the NPDG motif required for enzymatic active site metal ion
coordination.
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Figure 3 | Expression of MBTPS2 in OI and IFAP ﬁbroblasts. (a) Quantiﬁcation of MBTPS2 transcripts by real-time RT–PCR shows no
signiﬁcant differences. (b) S2P protein levels are normal in OI, IFAP and KFSD ﬁbroblasts, as detected by western blot. No signiﬁcant differences inMBTPS2
expression were detected between control and proband ﬁbroblasts. Error bars, s.d.
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cells lacking MBTPS2 (Fig. 4b). The transcriptional activation of
ATF6 after tunicamycin-induced ER stress was signiﬁcantly
decreased in CHO-M19 cells expressing mutant constructs
(p.N459S, p.L505F, p.R429H) versus normal MBTPS2 (Po0.01)
(Fig. 4b and Supplementary Table 7), as measured by luciferase
activity. Interestingly, the depression of ATF6 activation from
p.L505F transfection was less marked than with p.N459S or
IFAP-causing p.R429H. This is similar to the degree of impaired
OASIS cleavage in untreated mutant ﬁbroblasts, in which
p.N459S and IFAP cells had relatively more uncleaved OASIS
than did p.L505F cells, although all mutants did signiﬁcantly
impair cleavage versus control.
Studies of SRE reporter co-transfection with MBTPS2 expres-
sion constructs were done with only p.N459S and IFAP/KFSD
mutants (Fig. 4c, Supplementary Table 8). Luciferase activation
was suppressed in all cells expressing mutant constructs in
sterol-free media.
Effect of defective S2P on type I collagen biochemistry. Since
OI is a collagen-related bone dysplasia and fully processed OASIS
is reported to activate Col1a1 transcription13, we examined type I
collagen biochemistry in ﬁbroblasts and osteoblasts with mutant
S2P. Collagen transcripts were variable in mutant cells, with
decreased COL1A1 transcripts detected in ﬁbroblasts of OI
proband 1/I (p.N459S), IFAP (p.R429H) and KFSD (p.N508S)
ﬁbroblasts, but not in OI ﬁbroblasts or osteoblasts with the S2P
p.L505F mutation (Fig. 5a).
Fibroblasts from OI probands secreted a signiﬁcantly reduced
amount of type I collagen (20–73% of control), as did IFAP and
KFSD ﬁbroblasts (E40%) (Fig. 5b). Proband osteoblasts were
insufﬁcient for this assay. Electrophoretic migration of proband
collagen (Fig. 5c) was normal, consistent with normal thermal
stability (Tm) and helical resistance to proteolytic digestion at
physiologic temperature (Supplementary Fig. 5a,b). Collagen
deposited into matrix in culture by S2P p.N459S ﬁbroblasts from
P1/I had a decreased proportion of collagen containing mature
cross-links (10% versus 22% of collagen deposited by normal
control ﬁbroblasts) (Supplementary Fig. 5c), suggesting that
hydroxylation of the type I collagen K87 residue crucial to
crosslinking may be impaired.
Effect of mutant S2P on bone tissue and cells. Tissue and
osteoblast characteristics of OI were demonstrated in a bone
sample from P1/II (p.L505F). Osteoblasts differentiated in culture
revealed impaired expression of transcripts related to osteoblast
maturation and RIP pathways (Fig. 6). Alkaline phosphatase
(ALPL) expression is about half of control in mid- to late
differentiation. OASIS (CREB3L1) expression was signiﬁcantly
reduced throughout osteoblast differentiation. Mature OASIS
normally complexes with SMAD4 to upregulate expression of
matrix genes14. However, SMAD4 transcripts were reduced
throughout p.L505F osteoblast differentiation, underlying the
reduced expression of the proteoglycan matrilin-1 (ref. 15).
Interestingly, COL1A1 expression in P1/II osteoblasts was
comparable to control (Fig. 5a).
Collagen extracted directly from P1/II bone tissue had less than
half the normal level of hydroxylation of the lysine (K87) critical
for collagen crosslinking in both collagen alpha chains (43%
versus 90% control in a1(I), and 7% versus 43% control in a2(I))
(Fig. 7a and Supplementary Fig. 6). This is consistent with both
the proband’s increased urinary LP/HP ratio and reduced
crosslinked collagen deposited into matrix. However, hydroxyla-
tion of collagen carboxyl-terminal crosslink residues K930/933
was normal in each chain (Fig. 7a and Supplementary Fig. 6). The
enzyme responsible for modiﬁcation of the crosslinking lysine
(K87), lysyl hydroxylase 1 (LH1, encoded by PLOD1), was
substantially reduced in S2P p.L505F osteoblast lysates, although
the level of CyPB/PPIB, a foldase critical to LH1 function, was
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Figure 4 | Functional studies of theMBTPS2 variants. (a) Western blots of OASIS cleavage by S1P and S2P. Control ﬁbroblast and osteoblast lysates show
cleavage of OASIS to its mature active form (S1P/S2P cleaved). Cells from OI, IFAP and KFSD probands contain increased partially cleaved OASIS (S1P
cleaved) due to impaired cleavage by S2P (TUN, tunicamycin; ALLN, N-[N-(N-acetyl-L-leucyl)-L-leucyl]-L-norleucine). (b) Luciferase assays of MBTPS2
activation of ATF6 reporters upon induction of stress (þ ). Renilla luciferase was used to normalize the transfection efﬁciency. WT, N459S, R429H,
and L505F indicate that cells were transfected with normal or mutant MBTPS2 constructs. **P, wild-type versus empty vector, N459S, R429H, and
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transfected with normal or mutant MBTPS2 constructs. **P, wild-type versus empty vector, N459S, R429H and H171Fo0.001 by ANOVA. Error bars, s.d.
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normal (Fig. 7b)12,16. PLOD1/LH1 transcripts and protein
were not consistently reduced in OI or IFAP/KFSD ﬁbroblasts
(Supplementary Fig. 7).
Discussion
We identiﬁed an X-linked form of osteogenesis imperfecta in two
independent pedigrees. Phenotypic inheritance pattern, linkage
analysis and NGS were used to localize the causative gene in each
family to MBTPS2 at Xp22. The gene defects co-segregate with
the phenotype in each pedigree and all affected individuals are the
sons of obligate carriers. This gene identiﬁcation extends the
inheritance pattern of OI to include X-linked recessive. Notably,
the OI phenotype of theseMBTPS2 defects is distinct from that of
PLS3 mutations, which cause an X-linked form of osteoporosis
that is mostly apparent in middle-aged adults, but does cause
fractures in some children17. Unlike MBTPS2 defects reported
here which cause moderate to severe OI, PLS3 defects do not
cause a generalized bone dysplasia, changes in bone shape or
structure, or secondary features of OI.
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MBTPS2 encodes S2P, an integral membrane protein critical
to RIP and essential for cholesterol metabolism18. Mutations
previously reported to cause substitutions in S2P (Supplementary
Fig. 8) underlie a spectrum of dermatological conditions: IFAP
syndrome, characterized by a triad of ichthyosis follicularis,
atrichia and photophobia7, KFSD9, BRESHECK syndrome8 and
Olmsted syndrome19. The affected individuals in our OI
pedigrees do not have any symptoms associated with these
conditions, even into adulthood. Both OI-causing substitutions in
S2P are located in highly conserved intramembrane residues near
the carboxyl end of the protein, and likely contribute to a
specialized function. In Family I, the MBTPS2 missense mutation
results in a p.N459S substitution at the ﬁrst residue of the S2P
NPDG motif, which coordinates the zinc metal ion critical to
protease catalytic function10. In addition, the serine substitution
at this site introduces a potential O-GlcNAc glycosylation site
(http://www.cbs.dtu.dk/services/YinOYang/), and addition of a
bulky group might interfere with S2P interaction with its
substrates. The Family II MBTPS2 mutation results in S2P
p.L505F. This substitution, in which leucine is replaced with the
bulkier phenylalanine, is predicted to be pathogenic by multiple
mutation analysis programs and may also interfere with S2P
substrate interactions. Interestingly, the nearby p.N508S and
p.N508T have a mild IFAP and KFSD phenotype9, and most
IFAP mutations are located adjacent to this critical region
(p.R429-N508)20.
S2P and S1P span the Golgi membrane and function
sequentially in RIP to process crucial regulatory substrates
transported from the ER membrane in times of ER-stress or
sterol restriction, including OASIS, ATF6 and SREBP
(Fig. 7c)3,5,13,21. The mature processed proteins then enter the
nucleus where they activate pathways involved in cholesterol
homoeostasis, unfolded protein response and bone formation.
Our demonstration of S2P functioning in human bone
development is supported by prior studies on defects of RIP
components in animal models. Both S1P and S2P knockdown
zebraﬁsh showed abnormal cartilage development, independent
of lipid defects22. Cartilage-speciﬁc S1P knockout mice (S1Pcko)
have a lethal chondrodystrophy, with loss of hypertrophic
chondrocytes and absent endochondral bone formation23.
S1Pcko chondrocytes also display differential downregulation of
transcripts related to cholesterol and lipid biosynthesis24. In
addition, ablation of the RIP substrate OASIS, a bZIP
transcription factor, causes spontaneous fractures and severe
osteopenia in mice13 and homozygous deletion of CREB3L1
(OASIS) causes recessive OI in one family25.
The MBTPS2 mutations causing X-linked OI do not impair
MBTPS2 expression or destabilize S2P protein, nor do MBTPS2
mutations causing IFAP/KFSD. Instead, they disrupt S2P
processing of RIP substrates, interfering with their downstream
functions. First, both p.N459S and p.L505F ﬁbroblasts
and p.L505F osteoblasts display impaired OASIS cleavage.
OASIS/CREB3L1 expression is decreased in p.L505F osteoblasts,
as is the expression of its nuclear binding target SMAD4 (ref. 14),
which, along with the reduced expression of osteoblast
maturation marker alkaline phosphatase, indicates a broad
defect in osteoblast differentiation. SMAD4 in turn co-activates
transcription of matrix proteins such as matrilin-1 (ref. 15),
consistent with decreased expression of MATN1 in OI proband
P1/II’s osteoblasts. Second, type I collagen secretion is decreased
in ﬁbroblasts of all OI probands. The combination of normal
collagen expression and reduced collagen secretion found in
mutant MBTPS2 ﬁbroblasts differs from the expected decreased
SMAD4 transcriptional activation of Col1a1 (ref. 14), as well as
from the murine Oasis knockout, in which reduced Col1a1
expression was detected13. However, reduced collagen secretion
was not detected in ﬁbroblasts of patients with mutant CREB3L1
(OASIS)25. Furthermore, S1Pcko chondrocytes retain type IIB
procollagen due to a trafﬁcking defect but do not exhibit
decreased Col2a1 expression24. Finally, the activation of RIP
substrates ATF6 and SREBP during ER stress and sterol-free
conditions, respectively, were signiﬁcantly reduced in CHO-M19
cells transfected with reporter constructs containing mutant
versus normal MBTPS2.
Notably, bone tissue from one X-OI proband revealed an
underlying collagen-related defect. Type I collagen extracted
directly from P1/II bone had signiﬁcantly reduced hydroxylation
of helical lysine residue 87 (K87) in both alpha chains, consistent
with the proband’s increased urinary LP/HP ratio. Although bone
was not available from P1/I, his elevated urinary LP/HP ratio
suggests a similar effect on collagen crosslinking occurs in his
bone, while the LP/HP ratio was normal in two X-OI carriers and
IFAP/KFSD patients (Supplementary Table 2). K87 is critical for
collagen crosslinking in bone, which is a major contributor to
bone strength26. Similarly reduced hydroxylation of type I
collagen K87 to about half of wild-type control values occurs in
a Ppib/CyPB knockout mouse model of type IX OI12. In the Ppib
knockout mouse, the level of LH1/PLOD1, the enzyme which
modiﬁes K87, is normal, but its function is impaired by absence
of its PPIase, CyPB. In contrast, LH1 protein is reduced in
osteoblasts from X-linked OI proband P1/II by an unknown
mechanism, although the level of CyPB is normal. Thus, the bone
collagen defect in X-linked OI combines reduced collagen
secretion into matrix and impaired collagen crosslinking.
Disturbance of additional OASIS functions may contribute to
the severe skeletal phenotype of X-linked OI, including
apoptosis, downregulation of osteocalcin, osteopontin and bone
sialoprotein, and ER stress, which overlaps ATF6 activation27.
It is apparent that mutations at different positions in MBTPS2
cause distinct syndromes, with no evidence at this time to suggest
a spectrum disorder. A variety of skeletal malformations have
been reported in IFAP-family syndromes, speciﬁcally vertebral
malformation and cleft hands28. For example, the p.R429H
IFAP mutation studied in our reporter assays causes vertebral
abnormalities7,8. Short stature, inguinal hernia and microcephaly
have also been noted in some IFAP patients. However, IFAP
patients do not have the fracture susceptibility or generalized
bone dysplasia that are the hallmarks of OI. However, the
mechanism by which different mutations in MBTPS2 cause
totally different developmental disorders remains unclear. The
biochemical studies comparing X-linked OI and IFAP ﬁbroblasts
show no clear distinction between phenotypes in cleavage of RIP
substrates OASIS, ATF6 and SREBP. The major distinction
between syndromes resides in the urinary crosslinks, with
elevated LP/HP ratios in X-OI probands and not in X-OI
carriers or an IFAP patient. This presents a reasonable hypothesis
that impaired hydroxylation and crosslinking of bone collagen is
the critical distinction for X-OI versus IFAP. Future studies
elucidating the RIP pathways involved in bone development may
reveal tissue-speciﬁc differences in collagen post-translational
modiﬁcation and crosslinking, or critical S2P bone-related
substrates other than OASIS, ATF6 and SREBP. These studies
of RIP pathways in bone development are of fundamental
importance and will be facilitated by animal models and bone
samples from additional patients with both X-OI and IFAP.
Methods
Detailed case reports. Family I. The proband (P1/I; V7) of Family I, the Thai
pedigree, was delivered at 39 weeks gestation by caesarean section due to multiple
long bone fractures detected at 4 months gestation. His birth weight was 2,860 gm
(10th centile), length 45 cm (o3rd centile), head circumference 34 cm (40th
centile) and anterior fontanelle 5 5 cm. He had fractures of ribs, humeri, femora
and tibiae (Fig. 2a). The proband received pamidronate starting at age 3 weeks.
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He stood with support at 18 months. No additional fractures occurred through 24
months of age, when his weight was 10 kg (3rd centile), length 76.5 cm (50th centile
for a 13-month-old boy) and head circumference 47.8 cm (40th centile). He had
closed anterior fontanelle, positional plagiocephaly, blue sclerae, normal teeth,
pectus carinatum, straight spine and upper extremity long bones but bowing of
femora and tibiae. Karyotype showed normal 46, XY.
The pedigree contains 12 affected members, with seven living (Fig. 1a). Clinical
assessments and blood samples were obtained from 18 individuals, including six
affected (Supplementary Table 1). The proband’s 32-year-old mother was healthy
with normal weight, height and bone mineral density. The proband and his mother
had normal serum calcium, phosphorus, alkaline phosphatase and lipid proﬁles.
Affected adult males had fractures beginning during gestation, white sclerae,
normal teeth, head circumference 52–58 cm (within mean±2.5 s.d. for Thai
adults), variable scoliosis and pectal deformity, bowing of extremities with striking
anterior angulation of tibiae, generalized osteopenia and ﬁnal adult stature from
110 to 140 cm (50th centile for age 5–11 years).
Family II. Patient P1/II is a 26-year-old man (Fig. 2b and Supplementary
Fig. 2a). The pregnancy was uneventful and he was delivered spontaneously at
term. Birth weight was 2,970 g (10th–25th centile), with a length of 46 cm
(3rd–10th centile). Direct postpartal bowing of the distal humeri and the proximal
radii were indicative of osteogenesis imperfecta. Radiography showed bilateral
fractures of the clavicles, several rib fractures and a consolidated prenatal fracture
of the left femur (Supplementary Fig. 2b). Between age 14 months and 16 years,
numerous fractures occured after only minor and moderate traumatic events,
involving the femur 11 times (this stopped after the insertion of Bailey–Dubow
elongation rods at age 8 years), the humerus 7 times, the lower arm 2 times and the
tibia 3 times. Two fractures of the mandibulae occured after adequate traumatic
events. There were no new fractures until age 24 years when one traumatic fracture
of the lower leg occured. Treatment with 9mg kg 1 per day intravenous
bisphosphonate was started at age 13 for 3 years. Current height at the age of 26
years is 110 cm (50th centile for 6-year-old male) and weight is 37 kg. Moderate
kyphoscoliosis of the thoracic and lumbar spine is present. There are no signs of
dentinogenesis imperfecta and the sclerae are white. An active wheelchair is mainly
used. Unsupported standing is possible for a longer time; unsupported walking
only a few steps, with support 5–10m, and on a treadmill more than 1 km.
The maternal uncle P2/II is a 68-year-old man who was diagnosed with
osteogenesis imperfecta quite soon after birth. Fracture rate and bending of the
long bones were similar to P1/II. Since puberty, fractures are rarely observed unless
through adequate trauma. He has a severe connatal pectus excavatum. His current
height is 105 cm (50th centile for 5-year-old male) and his weight is 45 kg.
Kyphoscoliosis of the thoracic and lumbar spine is more pronounced than in his
nephew, and is rather progressive. He has no signs of dentinogenesis imperfecta
and his sclerae are white. He can walk slowly with two crutches.
Molecular genetic investigations of Family I. DNA from blood and dermal
ﬁbroblasts. Proband and family whole blood and skin samples were collected after
written informed consent was obtained under a protocol approved by the
Institutional Review Board of the Faculty of Medicine, Chulalongkorn University.
High-molecular-weight DNA was extracted from leukocytes of all the available
family members, and from cultured skin ﬁbroblasts of the proband, using the
ArchivePure DNA Blood Kit (5 PRIME Inc., Gaithersburg, MD), according to the
manufacturer’s instructions.
X-inactivation assay. Eight female members (III1, III5, III7, IV5, IV13, IV18,
IV21 and IV23) and one unaffected male (IV19) were subjected to X-inactivation
analysis as previously described29. A total of 500 ng blood-derived DNA was
digested with 10U of the methylation-sensitive enzyme HpaII at 37 C for 16 h
and enzyme-inactivated at 95 C for 10min. The ﬁrst exon of the androgen
receptor gene (AR) was ampliﬁed using a ﬂuorescently labelled forward primer
FAM-50-CGCGAAGTGATCCAGAACCC-30 and reverse primer 50-GTTGCTGTT
CCTCATCCAGG-30 in digested and undigested DNA templates. The polymorphic
CAG repeats in the AR gene were used to identify parental chromosomes.
Methylation differences were analysed based on peak heights in the PCR products
by Genemapper version 3.7 (Applied Biosystems, Foster City, CA).
Linkage analysis. Linkage analysis for Family I was performed according to the
previously described methods30. X-chromosomal microsatellite markers were PCR-
ampliﬁed using panel 28 of ABI Prism Linkage Mapping Sets-MD10 Version 2.5
(Applied Biosystems, Foster City, CA). An additional 21 polymorphic
microsatellite markers were used for ﬁne mapping on chromosome Xp22 between
DXS8051 and DXS1068 (Supplementary Table 3). All ﬂuorescently labelled
primers were typed on an ABI Prism 3100 genetic analyzer (Applied Biosystems,
Foster City, CA) with Genemapper version 3.7. For genetic mapping, the MLINK
program was used to calculate two-point linkage analysis with the following model:
X-linked recessive with high penetrance, disease and normal allele frequencies were
set at 0.01 and 0.99. Maximum logarithm of the odds (LOD) score using the
deduced genotyping of unavailable members was also shown in the bracket.
Linkage analysis of the X-chromosome using a panel of microsatellite markers
deﬁned a 21.6-Mb critical region from markers DXS7108 to DXS1067, with a
maximum LOD score of 3.31 (Supplementary Fig. 1a and Supplementary Table 3).
Mutation analysis of candidate genes. Candidate genes PIR, TRAPPC2, PHEX,
Cxorf15, AP1S2, CA5B, PDK3, PIGA, PRRG1, SMPX, were selected because of their
inferred biological relevance for connective tissue functions. HCCS, MSL3, PRPS2
on the telomeric end of the critical region were also studied. Primer pairs used for
ampliﬁcation of entire coding regions are available on request.
Sequencing of a set of genes involved in OI and bone fragility (ALPL, BMP1,
COL1A1, COL1A2, CREB3L1, CRTAP, FKBP10, IFITM5, LEPRE1, LRP5, PLOD2,
PLS3, PPIB, SERPINF1, SERPINH1, SP7, TMEM38B and WNT1) was performed
(CTGT, Allentown, PA). Screening of IFITM5 by PCR and Sanger sequencing was
normal. Sequencing of COL1A2 revealed a single heterozygous IVS30þ 6T4C
transition, which did not alter splicing (Supplementary Fig. 3). To determine the
functionality of the change, a 260-bp fragment of genomic DNA from the
OI proband, his mother, father and an affected male family member was
PCR-ampliﬁed using 1.5mM MgCl2, 0.2mM dNTPs, 200 nM forward (50-AGCCT
GTGTACTTATGCACT-30) and reverse (50-CAGTGGCTTTAAGGAGAAAG-30)
primers and 0.5U Taq DNA polymerase (Life Technologies, Grand Island, NY)
with 35 cycles of 94 C for 30 s, 58 C for 30 s and 72 C for 30 s. To conﬁrm that
the COL1A2 IVS30þ 6T4C transition was a nonfunctional genomic SNP, normal
mRNA splicing was veriﬁed by RT–PCR analysis using total RNA from control
and proband ﬁbroblasts treated with or without emetine. After removal of
contaminating DNA by treatment with DNA-free DNase (Applied Biosystems,
Foster City, CA), poly-A mRNA was reverse transcribed using oligo d(T) and
MuLV reverse transcriptase. The resulting cDNA was ampliﬁed from sequences
corresponding to a2(I) exons 25–32 using 1U Platinum Taq High Fidelity (Life
Technologies, Grand Island, NY) and 1.5mM MgSO4, 0.4mM dNTPs, 15 nmol
forward (50-CATTGGATTCCCTGGACCCAAAGGCCCCAC-30) and reverse
(50-GGAGTCCACTAGGACCAGATGGACCAGCAG-30) primers, and 35 cycles
of 94 C for 1min, 67 C for 20 s and 72 C for 45 s. PCR products were
electrophoresed on 6% polyacrylamide and visualized by ethidium bromide
staining.
Comparative Genomic Hybridization. CGH was performed on test DNA
(affected male, IV17) and reference DNA (unaffected male, IV10) for the
determination of copy number variants (Macrogen Inc., Seoul, Korea). DNAs were
independently labelled with ﬂuorescent dyes, co-hybridized to a NimbleGen
Human CGH 385K chromosome X Tiling array, and scanned using a 2-mm
scanner. Log2-ratio values of the probe signal intensities (Cy3/Cy5) were calculated
and plotted versus genomic position using Roche NimbleGen NimbleScan
software. Data are displayed in Roche NimbleGen SignalMap software. CGH did
not show any imbalances in the critical region.
Next-generation sequencing. We performed targeted resequencing by NGS of
the 18.6-MB linkage region between DXS1224 and DXS1067 interval on affected
male (IV17) and unaffected male (IV10) genomic DNAs (Macrogen Inc., Seoul,
Korea). DNA was captured on a customized NimbleGen 2.1 array (Roche
NimbleGen, Madison, WI) with a capturing capacity of 33 Mb. The targeted region
corresponded to positions 13,235,460 to 31,798,001 bp on Chromosome Xp22
according to the UCSC hg19 Assembly. Capture efﬁciency varied across the target,
with a mean read depth of 121.1X. The captured library was subsequently
sequenced using the Illumina platform Genome Analyzer II X (GAIIX) in a
single-end 76 bp conﬁguration. Sequence reads were mapped against UCSC hg19
using BWA software (http://bio-bwa.sourceforge.net/). The SNPs and Indels were
detected by SAMTOOLS (http://samtools.sourceforge.net/) and annotated by SIFT
(http://sift.jcvi.org/) (Supplementary Table 4). We found 25 variants in coding
sequences. After excluding known SNPs in dbSNP Build 135, 1000 Genomes and
HAPMAP, and variants present in the unaffected relative, two candidates remained:
c.1376A4G (p.N459S) in MBTPS2 and c.532G4A (p.V178M) in FAM48B1.
Mutation conﬁrmation and segregation studies. PCR ampliﬁcation and Sanger
sequencing were performed to conﬁrm the MBTPS2 mutation in the proband and
his parents. Primer pairs and PCR conditions for the ampliﬁcation of the coding
exons of MBTPS2 including the intron–exon boundaries are available on request.
Restriction enzyme digestion with BsgI was used for cosegregation study and
normal control screening. The identiﬁed mutation was analysed with ClustalX for
conservation analysis. Alamut, Polyphen2, SIFT, Panther and align GVGD were
used for prediction of mutation function.
Molecular genetic investigations of Family II. Sequencing of osteogenesis
imperfecta candidate genes. Exclusion of disease-causing mutations segregating
with the phenotype was performed for ALPL, BMP1, COL1A1, COL1A2, CREB3L1,
CRTAP, FKBP10, IFITM5, LEPRE1, LRP5, PLOD2, PLS3, PPIB, SERPINF1, SER-
PINH1, SP7, TMEM38B and WNT1 (CTGT, Allentown, PA). A heterozygous
c.4018G4A (p.G1340S) in COL1A1, reported as rs147936946 in the dbSNP
database was found in P1/II and his healthy father. This variant was absent in the
affected maternal uncle (P2/II), as well as in the proband’s mother (Supplementary
Fig. 3c).
Genome-wide linkage analysis. For the ﬁve living members of Family II
(Supplementary Fig. 1) a genome-wide linkage scan was performed using the
HumanCytoSNP-12v2 BeadChip (Illumina, San Diego, CA) according to the
supplier’s instructions. Raw SNP call data were processed with the Genotyping
Analysis Module in GenomeStudio 1.6.3 (Illumina, San Diego, CA). Homozygosity
mapping was performed with the Allegro program, under the assumption of a
recessive mode of inheritance in absence of consanguinity loops.
X-inactivation assay. X-inactivation analysis was performed on gDNA from the
mother of P1/II according to Beever et al31. PCR products were analysed on an ABI
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3130 Capillary DNA Sequencer (Applied Biosystems) and the methylation status
was analysed by Genemapper version 4.0 (Applied Biosystems) based on the peak
heights of the PCR products.
Exome enrichment and high-throughput sequencing. Genomic DNA was
extracted from whole blood using the MagNA Pure Compact System (Roche
Life Science, Indianapolis, IN, USA). DNA library preparation was performed with
the TruSeq DNA Sample Preparation Kit (Illumina, San Diego, CA) according to
the manual instructions. Enrichment of X-chromosomal genes was done by using a
custom designed NimbleGen Sequence Capture Microarray (solid array with 6962
targets on the X chromosome or 1.4Mb). The captured library was sequenced on a
MiSeq sequencer (Illumina, v1) with 2 150 cycles of paired-end sequencing.
Data analysis. Raw data processing, sequence read alignment from FASTQ to
BAM format and variant calling to generate VCF ﬁles were performed with the
MiSeqReporter Software (Illumina, San Diego, CA). Aligned BAM ﬁles with
removed duplicated reads were further technically analysed using the SeqMonk
program version v0.25.0 (http://www.bioinformatics.babraham.ac.uk/projects/
seqmonk). Variant ﬁltering was performed by GeneTalk (https://www.gene-talk.de/).
Mutation conﬁrmation and segregation study. Mutation screening of MBTPS2
and segregation analysis of the mutation within the family was performed by
ﬂuorescent bidirectional sequencing of genomic ampliﬁed PCR products on an ABI
3100 automated sequence detection system (Applied Biosystems, Foster City, CA,
USA). PCR conditions and primer sequences are available from the authors on
request.
Bioinformatics analysis aimed to predict pathogenicity of the identiﬁed L505F
variant was performed with Provean, Panther, MutationTaster and PolyPhen2.
Conservation analysis of the protein variant was performed by multiple sequence
alignment of MBTPS2 with ClustalX, ClustalW and BOXSHADE programs
(Fig. 2e).
Urinary pyridinoline analysis. Total urinary pyridinoline crosslinks, LP and HP,
were measured in the affected individuals and obligate carriers of Family I and
Family II, as well as in an MBTPS2 R429H IFAP patient and unaffected carrier
(Supplementary Table 2) by HPLC as described32.
Luciferase assay. CHO-M19 cells, a deleted Mbtps2 orthologous cell line, were
used for transfection of reporter constructs. Cells were maintained in Ham’s F-12
medium supplemented with 10% fetal bovine serum at 37 C with 5% CO2. We
performed luciferase assays by transient transfection of CHO-M19 cells either with
p5xATF6 or pSRE reporters as previously described5,7. The p5xATF6 and pSRE
reporters contain either an ER-stress response element or a sterol regulatory
element, respectively, two elements that are known targets of S2P. These assays are
an indirect measurement of the transcriptional activity of S2P cleavage products on
these two elements. For the p5xATF6 reporter, cells were set up at a density of
1.5 105 cells per well in triplicate in 12-well culture plates. Cells were transfected
with 1 mg of expression plasmid containing normal, mutant (N459S, R429H and
L505F) MBTPS2 or no insert, together with 800 ng of p5xATF6-GL3 and 50 ng of
pRL-SV40 as a transfection control. The total amount of DNA was adjusted to 2 mg
per dish by addition of pdEYFP-C1amp. At 24 h post-transfection, cells were
treated with 2 mgml 1 of tunicamycin dissolved in DMSO to induce stress.
Untreated cells received 0.2% DMSO. After incubation for 24 h, the ﬁreﬂy and
renilla luciferase activities were measured using a dual luciferase assay system
according to the manufacturer’s protocol (E1910 Promega kit, Madison, WI).
For the pSRE-reporter, cells were set up at a density of 1.5 105 cells per well
in triplicate in a 12-well plate. On day 2, the cells were switched to medium
containing 1:1 Ham’s F12:DMEM, 5% lipoprotein-deﬁcient serum and 20mM
sodium oleate for 7 h. The transfected plasmids were either wild-type S2P or one of
the three mutants (p.N459S, p.R429H, p.H171F) and the pSRE reporter. Cells were
then switched to medium containing 1:1 Ham’s F12:DMEM, 5% lipoprotein-
deﬁcient serum, 50mM compactin and 50mM mevalonate supplemented with
sterol (10mgml 1 cholesterol, 1mgml 1 25-hydroxycholesterol). Untreated cells
were treated with 0.2% ethanol (0.2% w/v). The ﬁreﬂy and renilla luciferase
activities were measured after 16 h of incubation. The ratio between ﬁreﬂy
luciferase and renilla luciferase luminescence from different constructs and control
was analysed by one-way analysis of variance (ANOVA). Speciﬁc pairwise
comparison between luciferase luminescence in each group used the least
signiﬁcant difference test. One-way ANOVA and least signiﬁcant difference
were included in SPSS software version 22.
Western blot analysis. Cell lysates from primary ﬁbroblasts and osteoblasts
were collected in RIPA buffer supplemented with a protease inhibitor cocktail
(Sigma-Aldrich, St Louis, MO), and used for western blotting of MBTPS2 (Cell
Signaling Technology, Danvers, MA), OASIS (R&D Systems, Minneapolis, MN)
and PLOD1/LH1 (Abgent Inc., San Diego, CA) proteins. Cells were grown to
conﬂuence and treated with tunicamycin (2 mgml 1), thapsigargin (1mM) and/or
ALLN (25 mgml 1) for 2 h before harvest. Protein lysate (50 mg) was loaded per
lane on a 4–20% (MBTPS2, PLOD1) or 10% (OASIS) Tris-Glycine Ready gel
(Bio-Rad, Hercules, CA), blotted onto 0.2 mm nitrocellulose and blocked with
Odyssey blocking buffer (MBTPS2) or 5% BSA plus 1 casein (OASIS, PLOD1)
before probing with antibody overnight. Blots were washed, incubated with
secondary IR-conjugated antibodies for 1 h, washed and visualized on a LI-COR
Odyssey infrared imager (LI-COR, Lincoln, NE).
Collagen biochemical studies. Dermal ﬁbroblast cultures were established from
skin punch biopsies and grown in Dulbecco’s Modiﬁed Eagle Medium (DMEM)
containing 10% fetal bovine serum (FBS), 100Uml 1 penicillin and 100 mgml 1
streptomycin.
For type I collagen biochemical studies, normal control and proband primary
ﬁbroblast and osteoblast (see below) cultures were labelled for 16 h in serum-free
DMEM containing 437.5 mCiml 1 L-[2,3,4,5-3H]-proline. Procollagens were
precipitated with ammonium sulfate, pepsin digested and electrophoresed on
6% SDS-urea polyacrylamide gels under nonreducing conditions33. Procollagen
secretion by control and proband ﬁbroblasts (Fig. 5b) was determined in 24-h
conditioned media using the Sircol collagen assay (Biocolor Ltd, Carrickfergus,
UK) according to the manufacturer’s speciﬁcations. Collagen protease sensitivity
was analysed as previously described34. For protease sensitivity assays, type I
collagen from the medium of cultured proband ﬁbroblasts labelled overnight with
437.5 mCiml 1 L-[2,3,4,5-3H]-proline was digested for 1, 3 and 5min with trypsin
and chymotrypsin (100 and 250mgml 1 ﬁnal concentration, respectively) at
37 C without prior cooling. Digests were stopped with 1mgml 1 soybean trypsin
inhibitor and analysed by SDS–urea PAGE.
Differential scanning calorimetry (DSC) was performed in buffer containing
0.2M sodium phosphate and 0.5M glycerol at pH 7.4, from 10 to 55 C in a
Nano III DSC instrument (Calorimetry Sciences Corporation, Lindon, UT),
as previously described35. Amino-acid composition was analysed by high pressure
liquid chromatography (AIBiotech, Richmond, VA).
Collagen extracellular matrix deposition was analysed as previously described36.
In brief, post-conﬂuent proband and normal control ﬁbroblasts were cultured for
2 weeks in DMEM containing 10% FBS with 100 mgml 1 ascorbic acid. After
14 days, ﬁbroblasts were labelled 24 h with 406.25 mCiml 1 L-[2,3,4,5-3H]-proline
and the media and extracellular matrix was harvested. Collagens were sequentially
extracted from the matrix with 150mM NaCl, 0.5N acetic acid and then
50 mgml 1 pepsin.
Expression studies. Total ﬁbroblast RNA was extracted from primary ﬁbroblasts
using TriReagent (Molecular Research Center, Cincinnati, OH), followed by DNase
treatment and RNA integrity veriﬁcation on an Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA). Complementary DNA was reverse transcribed from 5 mg RNA
using a High-Capacity cDNA Archive Kit (Life Technologies Corporation,
Carlsbad, CA). Taqman Gene Expression Assays were used to determine the
transcript level of MBTPS2 (Hs00210639_m1), COL1A1 (Hs00164004_m1),
COL1A2 (Hs00164099_m1), PLOD1 (Hs00609368_m1), CREB3L1
(Hs00223565_m1), ALPL (Hs01029144_m1), MATN1 (Hs00159075_m1) and
SMAD4 (Hs00929647_m1) (Life Technologies Corporation, Carlsbad, CA).
Relative expression of each gene of interest was compared with the expression of
GAPDH (Hs99999905_m1) and normalized to normal control primary ﬁbroblasts.
Osteoblast studies. Osteoblast primary cultures were established from surgical
bone chips and cultured in aMEM (Life Technologies, Grand Island, NY)
supplemented with 10% FBS, penicillin and streptomycin at 37 C and 8% CO2
(ref. 37). Only passages 1 and 2 were used for experiments. For differentiation,
osteoblast cultures were grown to conﬂuence and treated with differentiation
medium (aMEM containing 10% FBS, 25 mgml 1 L-ascorbic acid, dexamethasone
(10 8M), and 2.5mM 2-glycerophosphate for 3 weeks.
Mass spectral analysis of bone tissue collagen. Demineralized bone was
digested with bacterial collagenase and the resulting collagen-derived peptides were
separated by reverse-phase HPLC, as previously described32. Electrospray MS
was performed on in-gel trypsin digests and individual HPLC column fractions
using an LTQ XL ion-trap mass spectrometer equipped with in-line liquid
chromatography (Thermo Scientiﬁc, Waltham, MA) using a C4 5-mm capillary
column (300 150mm; Higgins Analytical RS-15M3-W045) eluted at
4.5 ml min 1. The LC mobile phase consisted of buffer A (0.1% formic acid in
MilliQ water) and buffer B (0.1% formic acid in 3:1 acetonitrile:n-propanol v/v).
The LC sample stream was introduced into the mass spectrometer by electrospray
ionization with a spray voltage of 4 kV. Proteome Discoverer search software
(Thermo Scientiﬁc) was used for peptide identiﬁcation using the NCBI protein
database. Proline and lysine modiﬁcations were examined manually by scrolling or
averaging the full scan over several minutes so that all of the post-translational
variations of a given peptide appeared together in the full scan.
Study oversight. This study was conducted according to the Declaration of
Helsinki for Human Rights and approved by Swiss Ethics and by the Institutional
Review Board of the Faculty of Medicine, Chulalongkorn University. Written
informed consent was obtained from the patients or their parents.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on request.
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